Edition:
India

BioCryst Pharmaceuticals Inc (BCRX.OQ)

BCRX.OQ on NASDAQ Stock Exchange Global Select Market

5.26USD
2:29am IST
Change (% chg)

$-0.06 (-1.13%)
Prev Close
$5.32
Open
$5.31
Day's High
$5.64
Day's Low
$5.25
Volume
480,560
Avg. Vol
358,844
52-wk High
$9.25
52-wk Low
$3.95

Select another date:

Mon, Jan 22 2018

BRIEF-Biocryst Pharma And Idera Pharma Sign Merger Agreement To Form New Company

* BIOCRYST PHARMACEUTICALS AND IDERA PHARMACEUTICALS ANNOUNCE MERGER TO COMBINE CAPABILITIES TO SERVE MORE PATIENTS WITH RARE DISEASES

BRIEF-Biocryst Advancing Potential Treatment For Rare And Severely Debilitating Fibrodysplasia Ossificans Progressiva

* BIOCRYST ADVANCING POTENTIAL TREATMENT FOR RARE AND SEVERELY DEBILITATING FIBRODYSPLASIA OSSIFICANS PROGRESSIVA

BRIEF-BioCryst Pharma files for mixed shelf of up to $200 million‍​

* Files for mixed shelf of up to $200 million - SEC filing‍​ Source text: (http://bit.ly/2m4wZHE) Further company coverage:

BRIEF-BioCryst Pharmaceuticals reports Q3 loss per share of $0.18

* Q3 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S

BRIEF-Biocryst’s Rapivab receives FDA approval for a pediatric indication

* Biocryst’s Rapivab (peramivir injection) receives FDA approval for a pediatric indication

BRIEF-Biocryst Pharmaceuticals prices public offering of common stock

* Biocryst Pharmaceuticals prices public offering of common stock

BRIEF-BioCryst Pharmaceuticals announces underwritten public offering​

* BioCryst Pharmaceuticals Inc - ‍offering to sell $80 million of its common stock in an underwritten public offering​

BRIEF-Biocryst announces positive results from mid-stage HAE trial

* Biocryst announces positive results from its Apex-1 Phase 2 trial in HAE

BRIEF-Biocryst Pharmaceuticals Q2 loss per share $0.21

* Q2 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S

Select another date: